Qiagen this week expanded its molecular diagnostics footprint by announcing its plans to acquire an undisclosed minority stake in Alacris Theranostics, a German startup company using bioinformatics to cull patients' genomic data for biomarkers that can be used to personalize cancer treatments.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.